Nama's AI scorecard currently rates Penumbra Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PEN's P/E ratio?

Penumbra trades at a trailing price-to-earnings ratio of 72.5.

When does PEN report earnings?

Penumbra's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $1.48.

What is the PEN price target?

The median analyst price target from 13 analysts is $374.00, with a range of $320.00 – $374.00.

Is PEN Shariah compliant?

Nama's AAOIFI-style screen reads Penumbra as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Penumbra (PEN)

Healthcare · Medical Devices · NYSE

Penumbra (PEN) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $12.58B, a trailing price-to-earnings ratio of 72.5 and a free-cash-flow yield of 1.4%. Over the most recent reported fiscal year, revenue grew 17.5% and free cash flow per share grew 18.7%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.6/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +19.6% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-11.9%

How far the last close sits under the highest price of the past five years.

Market cap	$12.58B
Trailing P/E	72.5
Price / book	8.2
Price / sales	8.1
FCF yield	1.4%
Dividend yield	—
Gross margin	67.8%
Operating margin	12.4%
Net margin	10.7%
Revenue growth (YoY)	+17.5%
Revenue growth (3-yr annual)	+18.3%
EPS growth (YoY)	+33.8%
FCF/share growth (YoY)	+18.7%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

PEN earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $1.48). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$1.20	$1.21	-0.8%	$410.14M
Q2 2026	Jul 30, 2026	$1.01	$1.18	-14.4%	$390.05M
Q1 2026	May 6, 2026	$1.01	$1.06	-4.7%	$374.76M
Q4 2025	Feb 25, 2026	$1.18	$1.11	+6.3%	$385.38M

PEN analyst price target

Median target $374.00 from 13 analysts, ranging $320.00 – $374.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live PEN data on Nama Insights →

Recent Congressional trades

Penumbra trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025

PEN FAQ

Is PEN a buy?: Nama's AI scorecard currently rates Penumbra Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PEN's P/E ratio?: Penumbra trades at a trailing price-to-earnings ratio of 72.5.
When does PEN report earnings?: Penumbra's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $1.48.
What is the PEN price target?: The median analyst price target from 13 analysts is $374.00, with a range of $320.00 – $374.00.
Is PEN Shariah compliant?: Nama's AAOIFI-style screen reads Penumbra as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.